CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 206 enrolled
Drug / intervention
Lorazepamdrug
Likely dose
Lorazepam 4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03905798
NCT03905798N/ACompleted

LORA-PITA (REGISTERED) Intravenous Injection 2 mg General Investigation

Pfizer·observational·Posted Apr 5, 2019·Updated Mar 10, 2025

In Brief

An observational study evaluating Lorazepam for Status Epilepticus. Completed, enrolled 206 participants across 1 site.

Detailed Summary

Secondary Data Collection:To confirm the effectiveness and safety profiles under the actual medical practice of LORA-PITA in Japan.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesJapan
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedApr 5, 2019
Enrollment StartNov 18, 2019
Primary CompletionNov 15, 2023
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 7.2 years ago

Interventions

Lorazepamdrug

The usual dose of lorazepam in adults is 4 mg administered intravenously. The drug should be given slowly with the administration rate at 2 mg/min as a guide. If necessary, 4 mg may be added but the dose should not exceed 8 mg as the sum of initial and additional doses. The usual dose of lorazepam in children aged 3 months or older is 0.05 mg/kg (up to 4 mg) administered intravenously. The drug should be given slowly with the administration rate at 2 mg/min as a guide. If necessary, 0.05 mg/kg may be added but the dose should not exceed 0.1 mg/kg as the sum of initial and additional doses.